title: Towards antivirals against chikungunya virus.
abstract: Chikungunya virus (CHIKV) has re-emerged in recent decades, causing major outbreaks of chikungunya fever in many parts of Africa and Asia, and since the end of 2013 also in Central and South America. Infections are usually associated with a low mortality rate, but can proceed into a painful chronic stage, during which patients may suffer from polyarthralgia and joint stiffness for weeks and even several years. There are no vaccines or antiviral drugs available for the prevention or treatment of CHIKV infections. Current therapy therefore consists solely of the administration of analgesics, antipyretics and anti-inflammatory agents to relieve symptoms. We here review molecules that have been reported to inhibit CHIKV replication, either as direct-acting antivirals, host-targeting drugs or those that act via a yet unknown mechanism. This article forms part of a symposium in Antiviral Research on "Chikungunya discovers the New World."
authors.affiliation: Rega Institute for Medical Research, University of Leuven, Belgium.
authors.forename: Rana
authors.initials: R
authors.lastname: Abdelnabi
authors.affiliation: Rega Institute for Medical Research, University of Leuven, Belgium. Electronic address: Johan.Neyts@rega.kuleuven.be.
authors.forename: Johan
authors.initials: J
authors.lastname: Neyts
authors.affiliation: Rega Institute for Medical Research, University of Leuven, Belgium.
authors.forename: Leen
authors.initials: L
authors.lastname: Delang
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000302:isolation & purification* / Q000494:pharmacology*; D002646:Chikungunya virus / Q000187:drug effects*; D055808:Drug Discovery / Q000639:trends; D006801:Humans
chemical_list: D000998:Antiviral Agents
keywords: Antiviral therapy; Arbidol; Chikungunya virus; Favipiravir; Monoclonal antibodies; Ribavirin